All In Biotech

Drug Trial Radar · NCT05676853

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

A Phase 3 Open-Label Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Last checked: Nov 20, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

3

Actual

Start

Apr 4, 2023

Primary completion

Apr 27, 2023

Study completion Apr 27, 2023

Sponsor

Lead sponsor
Aeglea BiotherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter study to evaluate the safety of weekly SC administration of pegzilarginase over 12 months in subjects with ARG1-D. The study consists of a screening period of up to 4 weeks, a subsequent 12-month treatment period, and a Safety Follow-Up Visit 2 weeks after the last treatment.

Conditions

  • Arginase I Deficiency
  • Hyperargininemia

Interventions

  • PegzilarginaseDrug

    Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent adverse eventsTime frame: Baseline through week 54

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital for Sick Children

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.